Truist Securities raises Terns Pharmaceuticals stock price target to $35 on positive ASH data
PositiveFinancial Markets

- Truist Securities has raised the stock price target for Terns Pharmaceuticals to $35 due to encouraging data from the ASH conference, indicating a positive outlook for the company.
- This increase in the price target signifies Truist's belief in Terns Pharmaceuticals' potential for growth and success in the market, particularly in light of the recent data.
- The move aligns with broader trends in the market where firms are increasingly evaluating and adjusting stock ratings based on emerging data and performance indicators.
— via World Pulse Now AI Editorial System

